Looking for an Alternative for Mounjaro? Here Is What the Evidence Says

The core decision: mechanism first, then match

Mounjaro works on two receptors simultaneously (GIP and GLP-1) which is why it sits in a category of its own as the UK's only dual-agonist weight-loss medicine. Its rivals work on one pathway or none. Understanding that difference is the starting point for comparing them honestly.

Wegovy (semaglutide injection) is a GLP-1 receptor agonist. It signals the brain to reduce appetite and slows how quickly the stomach empties. In the STEP 1 trial, published in the New England Journal of Medicine, participants on 2.4mg weekly lost an average of around 15% of body weight over 68 weeks alongside lifestyle changes. The SURMOUNT-5 head-to-head trial published in 2025 found tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks, but a 15% average reduction is still clinically meaningful for many people, and semaglutide's longer track record means more real-world safety data exists. Some patients also simply tolerate it better.

The practical question is not which medicine scores higher in a trial but which one your prescriber judges appropriate for you given your full health picture. A fuller comparison of the injectable options is covered on our Mounjaro treatment overview, and if you are researching what the pipeline holds beyond current approvals, the retatrutide comparison is worth reading too.

Wegovy tablets: the alternative that most people have not heard of yet

Wegovy tablets became the first oral GLP-1 medicine licensed for weight management in the UK when the MHRA approved them on 11 June 2026, making the UK the first country in Europe to grant that approval. The active ingredient is still semaglutide, but taken once daily in tablet form rather than injected once weekly.

The dosing ladder starts at 1.5mg and escalates through 4mg and 9mg to a 25mg maintenance dose, with at least a month at each level. In the OASIS 4 phase 3 trial, participants lost an average of around 13.6% of body weight over 64 weeks compared with roughly 2.4% on placebo. Among those who adhered fully to treatment, the average was closer to 17%, though that figure only applies to the fully-adherent group, not participants as a whole.

For someone who finds injections a barrier, this is a clinically meaningful alternative rather than a compromise. There is no refrigeration requirement, which makes it more travel-friendly, useful to know if you are planning anything around payday or a summer holiday when routine is already disrupted. The tablet does need to be taken first thing in the morning on an empty stomach with a small amount of plain water, with at least 30 minutes before food or other medicines.

Because it is newly approved, a NICE appraisal has not yet taken place, so it is not available on the NHS. You can explore all licensed options through our free consultation.

Orlistat: a different approach with a different fit

Orlistat does not affect appetite at all. It works in the gut, inhibiting lipase enzymes and blocking the absorption of roughly a third of the fat you eat. That unabsorbed fat passes through, which produces well-documented gastrointestinal side effects (oily stools, urgency, and leakage) particularly if fat intake is high. The side effects are, in a sense, the mechanism made visible.

The evidence base is older and the average weight loss in trials is more modest than with GLP-1 medicines. It is, however, the only weight-related option available in lower strength (60mg) without a clinical consultation. The prescription-strength version (120mg, three times daily with meals) requires the same clinical assessment as any other POM. The NHS medicines page on orlistat explains the full side-effect and dietary requirements clearly. For most people considering Mounjaro alternatives, orlistat is a genuinely different category of treatment rather than a like-for-like swap.

If you are researching orlistat primarily because of cost, our guide to Mounjaro pricing in the UK puts private treatment costs in context and may answer questions you did not know you had. And if your interest is more about what practical support looks like day-to-day on treatment, the tips for getting the most from Mounjaro page is useful background regardless of which medicine you ultimately use.

What the prescriber will actually weigh up

No alternative is automatically superior. A prescriber comparing options for a specific patient will look at: current BMI and whether it meets each medicine's licensed threshold; existing conditions (type 2 diabetes, cardiovascular risk, GI history); tolerance of injections; previous treatment history; and whether the patient has already tried one medicine without sufficient response.

The NICE appraisal of tirzepatide (TA1026) gives a sense of how the clinical system thinks about Mounjaro's place in treatment, and by implication, where the bar sits for switching or choosing an alternative. Age and eligibility boundaries also shape the conversation; the age requirements for Mounjaro page covers this specifically.

If you are switching from one medicine because of a supply issue rather than a clinical preference, that is worth flagging directly, supply context is relevant to prescribing decisions. Our Mounjaro substitute guide covers supply-related switching in more detail. You can also browse what our clinical team considers when reviewing alternative options on the clinical team profile.

The right starting point is a conversation with a prescriber who can look at your full picture. Speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, not software.